Key highlights first nine months 2023:

Sales € 1,091.0 million; an organic increase of 2.6%
Adjusted EBITDA € 142.8 million; an organic increase of 7.1%
Operating profit € 75.9 million; an organic growth of 0.2%
Organic growth core activities: Sales 4.2% & Adjusted EBITDA 12.3%
Q3 2023:
Sales € 353.0 million and Adjusted EBITDA € 46.0 million
Organic growth core activities: Sales -2.2% & Adjusted EBITDA 6.1%
Positive Free Cash Flow for the 2nd consecutive quarter as anticipated

Strategic Developments:

Restructuring program underway to accelerate significant positive free cash flow delivery, including a full review to drive material improvements in operating expenses, capital program and working capital
Broader auction process underway to divest the non-core emulsifier business in order to maximize value
Strategic review of Corbion’s position in PLA
Algae Ingredients roadmap 2025-2030 following strong growth prospect underway
Continued focus on high growth, high value biomedical business



€ million YTD 2023 YTD 2022 Total growth Organic growth
Sales 1,091.0 1,080.4 1.0% 2.6%
Adjusted EBITDA 142.8 142.8 0.0% 7.1%
Adjusted EBITDA margin 13.1% 13.2%
Operating profit 75.9 91.7 -17.2% 0.2%

Core activities
Sales 952.3 927.9 2.6% 4.2%
Adjusted EBITDA 121.5 116.6 4.2% 12.3%
Adjusted EBITDA margin 12.8% 12.6%

see & read more on
https://ml-eu.globenewswire.com/Resource/Download/9c8dfb03-ee61-4694-b899-c67b149566a5